Table 1.
Methylation levels of promoter CpG of CLDN4 gene in 157 BUC samples.
| Parameter | n | Methylation (%) | p | |
|---|---|---|---|---|
| Normal urothelium | 20 | 92 ± 5 | ||
| BUC | 157 | 72 ± 19 | <0.0001 | |
| Grade (1) | G1 | 23 | 81 ± 12 | |
| G2 | 39 | 77 ± 24 | ||
| G3 | 95 | 68 ± 20 | 0.0057 | |
| pT (2) | pTa | 61 | 82 ± 19 | |
| pTis | 23 | 75 ± 20 | ||
| pT1 | 34 | 73 ± 23 | ||
| pT2 | 39 | 69 ± 23 | 0.0215 | |
| Muscle | NMIBC | 118 | 78 ± 21 | |
| invasion | MIBC | 39 | 69 ± 23 | 0.0249 |
BUC, bladder urothelial carcinoma; CLDN, claudin; NMIBC, non-muscle invasion bladder cancer; MIBC, muscle invasion bladder cancer. (1) Histological grade; G1, well differentiated; G2, moderately differentiated; G3, poorly differentiated according to TNM classification system [18]. (2) pT, primary tumor; pTa, non-invasive papillary urothelial carcinoma; pTis, carcinoma in situ; pT1, subepithelial invasion; pT2, muscle invasion according to TNM classification system [18].